Associations of Polygenetic Variants at the 11q23 Locus and Their Interactions with Macronutrient Intake for the Risk of 3GO, a Combination of Hypertension, Hyperglycemia, and Dyslipidemia

Jun-Yu Zhou 1 and Sunmin Park 1,2,*

1 Department of Bio-Convergence System, Hoseo University, Asan 31499, Korea; zjy888zjy888@gmail.com
2 Department of Food and Nutrition, College of Life and Health Sciences, Hoseo University, Asan 31499, Korea
* Correspondence: smpark@hoseo.edu; Tel.: +82-41-540-5633; Fax: +82-41-540-5630

Abstract: 3GO is a condition in which hypertension, hyperglycemia, and dyslipidemia co-occur, and these conditions are related to each other and genetic and environmental factors. We hypothesized that common genetic variants and their interactions with lifestyles influenced 3GO risk. We aimed to explore common genetic variants to affect 3GO risk and their haplotype interaction with lifestyles in a city hospital-based cohort in 58,701 Koreans > 40 years. 3GO was defined as SBP ≥ 140 mmHg and DBP ≥ 90 mmHg for hypertension, fasting blood glucose ≥ 126 mg/dL for hyperglycemia, and LDL ≥ 160 mg/dL or HDL ≤ 40 mg/dL, or triglyceride ≥ 200 mg/dL for dyslipidemia. Haplotypes were generated by genetic variants selected from genome-wide association study (GWAS) after adjusting for age, sex, area of residence, and body mass index (BMI). Nutrient intakes were assessed using food frequency questionnaires. Interactions between haplotype and lifestyles and 3GO risk were investigated. Parameters related to metabolic syndrome were significantly different in the 0GO, 1–2GO, and 3GO groups, that is, groups of individuals with none, one to two, or all three of the components of 3GO. At the 11q23 locus, KCNQ1_rs2237892, ZPR1_rs2075291, APOA5_rs662799, APOA1_rs5072, and SIK3_rs151139277, influenced 3GO risk, and the minor alleles of their haplotype had a 3GO risk 3.23 times higher than the major alleles. For subjects with a high energy intake, the 3GO risk of the minor alleles was significantly higher than that of the major alleles (OR = 3.230, 95% confidence interval (CI) = 2.062~5.061, p < 0.001). BMI, HbA1c, SBP, and serum concentrations of glucose, HDL, and triglyceride were significantly higher for the minor allele than the major alleles (p < 0.001). The haplotype interacted with the intakes of protein (p = 0.033), digestible carbohydrate (p = 0.012), fat (p = 0.008), and undigestible carbohydrates (p = 0.015) to increase 3GO risk. An interaction was also observed between smoking and the haplotype (p = 0.007). The minor allele effects on 3GO incidence were higher in the high digestible carbohydrate intake and smoking groups. By contrast, the minor allele impacts on 3GO frequencies were much higher in the low intake of undigestible carbohydrates, protein, and fat. In conclusion, people who carry a minor allele of the 11q23 locus haplotype should avoid smoking and replace digestible carbohydrate intake with consuming high-quality protein, healthy fat, and undigestible carbohydrates.

Keywords: hypertension; hyperglycemia; dyslipidemia; haplotype; 3GO; undigested carbohydrates; dietary fiber

1. Introduction

The World Health Organization has stated that reducing metabolic syndrome (MetS) development should be considered the first defense against cardiovascular diseases [1].

J. Pers. Med. 2021, 11, 207. https://doi.org/10.3390/jpm11030207

https://www.mdpi.com/journal/jpm
The mortality rate related to cardiovascular diseases is as high as 35.7% in Asians [2]. Early-stage MetSe has the characteristics of abdominal obesity, hypertension, hyperglycemia, and dyslipidemia, and progresses to metabolic diseases such as type 2 diabetes (T2DM) and cardiovascular diseases [1]. The components of MetS also influence the development and progression of metabolic diseases. Although abdominal obesity plays a vital contributor role, Asians that develop hyperglycemia lose weight, and thus, in Asians, abdominal obesity and obesity do not significantly affect metabolic diseases [3]. Relatively lean Asians develop hyperglycemia, hypertension, and dyslipidemia [3].

The other three components of MetS (hypertension, hyperglycemia, and dyslipidemia) are closely interrelated and share risk factors, such as aging, menopause, obesity, inflammation, and oxidative stress [1]. Hypertension, hyperglycemia, and dyslipidemia share insulin resistance as a common mechanism [4]. According to a recent report, about 40% of diabetic patients have lipid metabolism disorders, as evidenced by high triglyceride and low high-density lipoprotein levels, T2DM causes dyslipidemia because lipoprotein lipase activity is reduced due to reduced insulin activity [5]. Moreover, those with T2DM exhibit increased lipid synthesis in the liver, which contributes to dyslipidemia and the development of non-alcoholic fatty liver [6]. Dyslipidemia increases blood vessel thickness by cholesterol deposition and thus, elevates blood pressure. Hypertension is also common in patients with T2DM and dyslipidemia [5]. Hypertension, hyperglycemia, and dyslipidemia are also substantial risk factors of cardiovascular and cerebrovascular diseases [7], and genetic and environmental factors influence the development of all three MetS components. Specific genetic variants have been reported to enhance susceptibilities to hypertension, hyperglycemia, and dyslipidemia [8,9], and some of these genetic variants are possibly shared, which suggests hypertension, hyperglycemia, and hyperglycemia should be simultaneously addressed [10].

Relatively non-obese Asians with MetS are susceptible to progress to T2DM, dyslipidemia, and hypertension. 3GO is a newly coined word for a syndrome comprised of hypertension, hyperglycemia, and dyslipidemia, and it is well-recognized in China since these diseases often simultaneously occur in one person [11,12]. GO corresponds to ‘high’ in the East Asian cultural sphere, including Chinese, Korean, Japanese, Vietnam, and Singapore [13], and 3 represents its three components. The cutoff values used to define 3GO are better-specified disease status than those for MetS, and 3GO indicates the co-existence of T2DM, hypertension, and dyslipidemia [14]. Accordingly, the prevention of 3GO may reduce mortality and morbidity and reduce medical costs. In this study, we hypothesized that common genetic variants influence 3GO risk and that they interact with lifestyles. Therefore, the study aimed to explore common genetic variants of 3GO risk, and the PRS of the common genetic variants interacted with lifestyles to influence 3GO risk in a city hospital-based cohort in Korean adults ≥ 40 years. The results of this study could be applied to prevent 3GO in those at elevated 3GO risk by modifying lifestyles, including smoking, drinking alcohol, nutrient intake, and exercise, according to genetic status.

2. Materials and Methods

2.1. Study Population

The epidemiological data used to represent the Korean urban population was obtained from the Korean Genomics and Epidemiology Study (KoGES) conducted by the Korean Center for Disease Control and Prevention. The Institutional Review Board of the Korean National Institute of Health (KBP-2015-055) approved the study protocol. All participants volunteered to take part in the study and provided written informed consent. Before conducting the research, we also obtained approval from the Institutional Review Board of Hoseo University (1041231-150811-HR-034-01). KoGES was initiated in 2004 and terminated in 2013 and was a population-based, prospective cohort study that recruited 58,701 Korean adults aged 40–77 years (20,293 males and 38,408 females). Follow-up surveys are conducted every two years, and study participants were followed up to 5 times...
during the 10-year study period. Information about lifestyles, current medications, and sociodemographic characteristics was obtained by a questionnaire-based survey.

2.2. Sociodemographic Characteristics and Biochemical Measurements

Questionnaires provided details of residence area, gender, age, smoking, drinking, and exercise status. Physical activity was estimated by multiplying rated physical activity intensities by times per week. Physical activity was classified as light, moderate, and heavy, based on moderate physical activity for <30, 30–120, and >120 min/week. Participants were classified as current, past, and never smokers. Never smokers had a lifetime smoking history of <100 cigarettes, and past-smokers had not smoked during the previous six months. Alcohol intake was assessed by multiplying the amount of drinking per occasion by the number of occasions per week, and daily alcohol intakes were classified as none (0 g), light (<2 g), moderate (2–20 g), or heavy (>20 g).

After at least 10 min rest upon arrival to the hospital between 7:00 a.m. and 9:00 a.m., blood pressure was measured at the upper right arm in a sitting position three times using a mercury sphygmomanometer (Baumanometer; WA Baum, Copiague, NY, USA) using a standard protocol [14,15]. There was a 5 min resting period between each measurement, and the average of three measurements was used for systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood samples were collected in a serum separator tube and two ethylenediaminetetraacetic acids (EDTA) tubes during mornings after an overnight fast for at least eight hours (drinking water was allowed) and no taking any medication in the morning before taking blood [14]. Serum and plasma were separated, aliquoted, and frozen for further assays [14]. The serum concentrations of glucose, high-density lipoprotein (HDL), triglycerides, and HbA1c were measured using a Hitachi automatic analyzer 7600. Body mass indices (BMI) were calculated by dividing body weight (kg) by height (m²), and obesity was defined as a BMI ≥ 25 kg/m².

2.3. 3GO Definition

According to the International Hypertension Federation [16], the diagnostic criteria for hypertension (regardless of gender) are SBP of ≥140 mmHg and DBP of ≥90 mmHg. The diagnostic criterion for hyperglycemia was applied to T2DM criteria: a fasting serum glucose of ≥126 mg/dL and taking anti-diabetic medication daily [17,18]. Dyslipidemia was defined as serum levels of triglyceride, total cholesterol, and HDL of ≥200, ≥250, or <40 mg/dL, regardless of gender, according to the guidelines issued by the International Society of Endocrinology [19]. The participants who took medications for hyperglycemia, hypertension, and/or dyslipidemia were considered the case of each group. 3GO (case) was defined as the presence of all three components, including hypertension, hyperglycemia, and dyslipidemia, while 1–2GO indicated having one or two among 3GO components. The participants without any 3GO components were considered as 0GO (control).

2.4. Dietary Assessment and Dietary Patterns

Usual food intakes were assessed using a semi-quantitative food frequency questionnaire (SQFFQ) composed of 103 food items, and frequencies and average serving sizes were obtained for each food item. Serving sizes were assessed as 0.5, 1, or 2 times a reference serving size. Average intakes were calculated for all food items by multiplying frequencies and average daily serving sizes. The validity and reproducibility of the SQFFQ were confirmed using a 3-day food record as previously described [20]. Dietary patterns were generated by principal component analysis using SQFFQ results. Daily energy and nutrient intakes were calculated using Can-Pro 2.0 nutrient intake assessment software devised by the Korean Nutrition Society [21].

2.5. Genotyping and Quality Control

According to standard protocols, genomic DNA was extracted from peripheral blood monocytes of all participants using the QuickGene DNA whole-blood kit with QuickGene-
610 L equipment (Fujifilm, Tokyo, Japan). Single nucleotide polymorphisms (SNP) were identified using a Korea Biobank array (K-CHIP), which contained 830,000 SNPs customized for Koreans (Affymetrix, Santa Clara, CA, USA) and designed by the Center for Genome Science of the Korea National Institute of Health (http://www.cdc.go.kr/CDC/eng/mobile/CdcKrContentView.jsp?cid=74266&menulds=HOME001-NU1130-MNU1890 (accessed on 18 March 2020)). After genotyping, genotyping accuracy was assessed by Bayesian Robust Linear Modeling with the Mahalanobis Distance genotyping algorithm [22,23]. The experimental results of the Korea Biobank Array were filtered by the quality control procedures of the following exclusion criteria: low genotyping accuracy (<98%), high missing genotype call rate (≥4%), high heterozygosity (>30%), gender bias, no satisfying Hardy–Weinberg equilibrium (HWE; \( p < 1 \times 10^{-5} \)), and a minor allele frequency (MAF) of <1% [22].

2.6. Screening of Genetic Variants and Generation of the Haplotype for 3GO Risk

Genetic variants were selected from genome-wide association study (GWAS) results for the 3GO risk, where GWAS was conducted using EditPlus software after adjusting for age, gender, residence area, and BMI. Genetic variants affecting 3GO risk were selected using \( p < 5 \times 10^{-6} \) since genetic effects were determined by haplotype. Subsequently, SNP-related genes were identified by searching the SCAN annotation database site (http://scandb.org/newinterface/ (accessed on 22 July 2020)). Linkage disequilibria (LD) were determined to check for correlations between SNPs in the selected locus of the chromosome using Locus Zoom (\( r^2 \) value < 0.3).

The haplotype was generated from the selected 5 SNPs in the 11q23 locus, and polygenic scores (PRS) of the haplotype were estimated by adding the number of risk alleles in each genetic variant. PRS of the haplotype was divided into three groups: 0–3 (major alleles), 4–6 (heterozygous alleles), and ≥7 (minor alleles). Haplotype alleles were used to estimate genetic and genetic \( \times \) lifetime impacts on 3GO.

2.7. Interactions between PRS and Lifestyles on 3GO Risk

The impacts of interactions between genetic variants and lifestyles on 3GO risk were analyzed. Daily energy, protein, fat, carbohydrate, Ca, coffee and alcohol intake, smoking status, and physical activity were included in the interaction analysis as lifestyle variables. Dietary intakes, smoking statuses, and physical activities were dichotomized as ‘high’ or ‘low’ about median values. Residence area, age, gender, BMI, smoking, drinking status, coffee, energy, fat, carbohydrate, cholesterol intakes, physical activity, and plasma total cholesterol concentration were included as covariates in the interaction regression model.

2.8. Statistical Analysis

Statistical analysis was performed using SPSS Ver. 24.0 (IBM SPSS Statistics). Descriptive statistics of categorical variables, such as gender and dietary frequency distribution, were obtained using the chi-square test. Descriptive statistics of continuous variables are presented as means and standard deviations (SDs). Covariates for adjustment were as follows: age, gender, area of residence, BMI, daily energy intake, cholesterol intake, fat intake percentages, physical activity, smoking status, and alcohol consumption. Five SNPs in the identified chromosome 11 (the 11q23 locus) were used for haplotype analysis. The major, heterozygous, and minor alleles of the haplotype were scored as 0, 1, and 2, respectively. The Chi-square test was used to analyze the frequency distributions of categorical variables. One-way analysis of variance (ANOVA) was used to determine the significances of differences between the control, 1–2GO, and 3GO groups after covariate adjustment for age, gender, area of residence, and BMI. One-way ANOVA was used to determine the differences between haplotype groups after adjusting for age, gender, residence area, and BMI. Duncan’s test was used to determine multiple comparisons among the groups if ANOVA was significantly different among the groups of each parameter. Multivariate logistic regression analysis controlled for covariates was used to determine the adjusted
odds ratio (OR) and 95% confidence interval (CI) of the haplotype for the risk of 3GO and its components. Multivariate interaction regression models were used to evaluate the impacts of interactions between haplotype alleles and lifestyles on 3GO risk, after adjusting for covariates of age, gender, residence area, and BMI (model 1), and those for model 1, physical activity, and energy, alcohol, and coffee intake (model 2). When a significant interaction was found, the lifestyle variable concerned was dichotomized into low and high groups, and in each group, adjusted OR and CI between the haplotype and 3GO risk were estimated. Statistical significance was accepted for \( p \)-values < 0.05.

3. Results

3.1. General Characteristics of the Participants

Of the 58,701 individuals that participated in KoGES, 1454 (2.48%) had 3GO. In the 2GO group, 2695 (4.59%) had hypertension and hyperglycemia, 6413 (10.9%) had hypertension and dyslipidemia, and 2969 (0.51%) had dyslipidemia and hyperglycemia (Figure 1). A total of 16,730 among 58,701 participants had all or either hypertension, hyperglycemia, or dyslipidemia. The average age of patients in the 3GO group was about seven years greater than that in the control group. Interestingly, most of the variables related to MetS were significantly different in the control, 1–2GO, and 3GO groups. BMI, waist circumferences, hip circumferences, and body fat percentages were reduced in 3GO, 1–2GO, and control groups. Mean waist circumference and body fat percentage were much higher in the 3GO group, by 9.1 cm and 6.2 % respectively, than in the control group (Table 1). Fasting serum glucose concentrations showed that only participants in the 3GO group had a level > 126 mg/dL. Serum lipid profiles showed that participants in the 3GO group had higher serum triglyceride concentrations and lower serum HDL cholesterol concentrations. The average lipid profiles in the 3GO group were lower than the diagnostic criterion since the participants having lipid-lowering medications were included as the 3GO case. Serum triglyceride concentrations showed the most significant differences, and the gap between the 3GO and control groups was 79.7 mg/dL. The mean serum triglyceride concentrations were 1.86 times higher in the 3GO group. SBP and DBP were also much higher in the 3GO group, by 15 and 7.2 mmHg respectively, than the control group (Table 1).

Figure 1. Numbers and percentages of participants with dyslipidemia, hypertension, or hyperglycemia.
Table 1. General characteristics of the study population according to 3GO.

|                          | Control (n = 28,440) | 1-2Go (n = 28,807) | Case (3GO) (n = 1454) | p-Value 1 |
|--------------------------|----------------------|---------------------|-----------------------|-----------|
| Gender (Number, male %)  | 7712 (27.1)          | 11,413 (40.7)       | 722 (49.7)            | <0.0001   |
| BMI 2 (kg/m²)            | 23.1 ± 2.7 c         | 24.5 ± 2.9 b        | 25.8 ± 3.1 a          | <0.0001   |
| Waist circumference (cm) | 78.2 ± 8.1 c         | 82.9 ± 8.3 b        | 87.3 ± 8.4 a          | <0.0001   |
| Hip circumference (cm)   | 93.2 ± 5.6 c         | 94.8 ± 5.8 b        | 96.2 ± 6.5 a          | <0.0001   |
| Body fat (%)             | 16.7 ± 7.1 c         | 17.6 ± 7.0 b        | 22.9 ± 6.5 a          | <0.0001   |
| Serum glucose (mg/dL)    | 89.7 ± 9.3 c         | 98.7 ± 22.5 b       | 132.4 ± 40.3 a        | <0.0001   |
| HbA1c (%)                | 5.53 ± 0.4 c         | 5.81 ± 0.8 b        | 7.09 ± 1.3 a          | <0.0001   |
| Total cholesterol (mg/dL)| 191 ± 26.2 b         | 204 ± 41.4 a        | 188 ± 43.9 c          | <0.0001   |
| HDL 3 (mg/dL)            | 57.4 ± 11.7 a        | 50.8 ± 13.5 b       | 45.7 ± 11.9 c         | <0.0001   |
| TG 4 (mg/dL)             | 92.3 ± 37.9 c        | 144 ± 73.8 b        | 172 ± 80.7 a          | <0.0001   |
| SBP (mmHg)               | 118 ± 12.6 c         | 127 ± 15.3 b        | 133 ± 15.1 a          | <0.0001   |
| DBP (mmHg)               | 73.0 ± 8.5 c         | 78.3 ± 10.1 b       | 80.2 ± 10.1 a         | <0.0001   |
| Total activity (Number, %)|                      |                     |                       |           |
| None or little (<90 min/w)| 12,749 (45.9)        | 12,773 (46.5)       | 685 (48.1)            | 0.231     |
| Moderate (90–150 min/w)  | 9315 (33.5)          | 9113 (48.3)         | 443 (31.1)            |           |
| Heavy (>150 min/w)       | 5724 (20.6)          | 5550 (20.3)         | 297 (20.8)            |           |
| Alcohol intake (g/day)   |                      |                     |                       |           |
| Non-drinker (<1)         | 15,008 (52.9)        | 14,312 (51.2)       | 717 (64.1)            |           |
| Light drinker (1–15)     | 782 (2.9)            | 1302 (4.7)          | 99 (34.3)             | <0.0001   |
| Moderate drinking (15–30)| 8252 (29.4)          | 8112 (28.9)         | 422 (29.1)            |           |
| Heavy drinker (>30)      | 4175 (14.8)          | 4206 (14.7)         | 211 (14.5)            |           |
| Coffee intake (cups/day) |                      |                     |                       |           |
| Non-drinker (0)          | 4588 (16.2)          | 4630 (16.5)         | 262 (18.1)            | 0.225     |
| Light drinker (<2)       | 4727 (16.7)          | 4675 (16.8)         | 240 (16.6)            |           |
| Moderate drinker (2–10)  | 14,208 (51.1)        | 13,797 (49.2)       | 708 (48.9)            |           |
| Heavy drinker (>10)      | 4735 (17.2)          | 4766 (16.9)         | 236 (16.4)            |           |
| Smoking (Number, %)      |                      |                     |                       |           |
| Non-smoking              | 6631 (23.3)          | 6241 (22.3)         | 290 (19.9)            | <0.0001   |
| Past-smoking             | 959 (3.4)            | 1607 (5.7)          | 95 (6.5)              |           |
| Heavy smoking            | 676 (2.4)            | 1121 (4.0)          | 60 (4.1)              |           |
| Energy intake (EER 5 percent) | 92.2 ± 29.3 a       | 91.4 ± 28.5 b       | 89.3 ± 28.5 c         | <0.0001   |
| Carbohydrate intake (energy percent) | 71.3 ± 7.0 b       | 72.1 ± 7.0 b       | 72.8 ± 6.7 a          | <0.0001   |
| Protein (energy percent) | 13.5 ± 2.5 a        | 13.4 ± 2.6 ab      | 13.2 ± 2.5 b          | <0.0001   |
| Fat intake (energy percent) | 14.3 ± 5.4 b        | 13.5 ± 5.4 a       | 12.8 ± 5.2 a          | <0.0001   |
| Undigested carbohydrates (g/1000 kcal) | 5.74 ± 2.83 a   | 5.70 ± 2.84 a      | 5.45 ± 2.65 b         | <0.0001   |
| Na (mg)/1000 kcal        | 2432 ± 1359 b       | 2446 ± 1404 a       | 2382 ± 1463 c         | 0.143     |
| Ca (mg/day)              | 450 ± 258 a         | 440 ± 256 b         | 414 ± 232 c           | <0.0001   |

The values represent adjusted means ± standard deviations or the number of the subjects (percentage of each group). 1 The statistical analysis for comparing continuous variables was conducted with one-way analysis of variance (ANOVA) after adjusting for age, sex, residence area, survey year, body mass index (BMI), smoking, physical activity, intake of energy, fat percent, carbohydrate percent, cholesterol, coffee, alcohol, and menopause. The statistical analysis for categorical variables was analyzed with χ² tests. Means without a common letter differ in the same row by Tukey’s test at p < 0.05. 2 BMI, body mass index; 3 HDL, high-density lipoprotein; 4 TG, triglyceride; 5 EER, estimated energy requirement.

Total physical activity and coffee intake were not significantly different in the three groups, whereas alcohol drinking and smoking were. Interestingly, energy intake, which was calculated as a percentage of estimated energy requirement, was lower in the 3GO group than the other two groups (Table 1). In terms of nutritional intake, participants in the 3GO group had a higher mean carbohydrate intake than those in the other groups, while protein and fat intake in the 3GO group were lower than in the control group. Ca and undigested carbohydrate (dietary fiber) intakes were also lower in the 3GO group than in the other groups (Table 1). These results suggest that the incidences of hypertension, hyperglycemia, and dyslipidemia are positively associated with improper nutrient intake,
regardless of energy intake, alcohol intake, and smoking status, and negatively related to exercise.

3.2. Selection of Genetic Variants

After adjusting for age, gender, area of residence, BMI, smoking status, coffee intake, drinking status, total activity, and total cholesterol, 5 SNPs selected from the 11q23 locus were found to influence 3GO risk (Table 2), and all 5 satisfied the Hardy–Weinberg equation \((p > 0.05)\) and MAF (>0.1). Four of the 5 SNPs, except rs2237892, were positively associated (OR = 1.202~1.875; \(p = 7.49 \times 10^{-6}^{−2.17 \times 10^{-11}}\)) with 3 GO risk (Table 2). The genes of these genetic variants were related to lipoprotein metabolism, APOA5 (apolipoprotein A5) rs662799, APOA1 (apolipoprotein A1) rs5072, ZPR1 (zinc finger protein) rs2075291, and SIK3 (SIK family kinase 3) rs151139277. No LD was observed among the SNPs (Figure 2). KCNQ1 (potassium voltage-gated channel subfamily Q member 1) rs2237892 exhibited a negative relationship with 3GO risk (Table 2).

Table 2. Characteristics of genetic variants to influence 3GO risk selected by genome-wide association study (GWAS) in a Korean city hospital-based cohort.

| Chr | SNP      | Position | Mi | Ma | OR       | p_Adjust | MAF | p_HWE | Gene          | Functional Consequence |
|-----|----------|----------|----|----|----------|----------|-----|-------|---------------|-----------------------|
| 11  | rs2237892| 2839751  | T  | C  | 0.8155   | 1.41 \times 10^{-6} | 0.3755 | 0.3933 | KCNQ1_rs2237892 | intron variant         |
| 11  | rs2075291| 116661392| A  | C  | 1.585    | 2.17 \times 10^{-11} | 0.0793 | 0.3655 | ZPR1_rs2075291 | upstream transcript variant |
| 11  | rs662799  | 116663707| G  | A  | 1.355    | 2.90 \times 10^{-12} | 0.2988 | 0.2874 | APOA5_rs662799 | upstream transcript variant |
| 11  | rs5072   | 116707583| A  | G  | 1.202    | 7.49 \times 10^{-6}  | 0.3593 | 0.8018 | APOA1_rs5072 | intron variant         |
| 11  | rs151139277 | 116753093 | T  | C  | 1.875    | 2.85 \times 10^{-7}  | 0.0192 | 0.7412 | SIK3_rs151139277 | downstream transcript variant |

*p*-value for ORs after adjusting for age, gender, residence area, and BMI; g Minor allele frequency; h Hardy–Weinberg equilibrium.

Figure 2. Linkage disequilibrium (LD) of KCNQ1_rs2237892, ZPR1_rs2075291, APOA5_rs662799, APOA1_rs5072, and SIK3_rs151139277, as determined by Locus Zoom.
3.3. Adjusted Means of MetS and Its Components According to 3GO and Haplotype Groups

The haplotype was generated by KCNQ1_rs2237892, ZPR1_rs2075291, APOA5_rs662799, APOA1_rs5072, and SIK3_rs151139277 in 11q23. It showed that 14,317, 13,118, and 1005 in the control participants belonged in the major, heterozygous, or minor alleles of the haplotype (Table 3). On the other hand, in 3GO patients, 210 had the major haplotype, 1131 had a heterozygous haplotype, and 113 had the minor haplotype. Regarding genetic impacts, fasting serum glucose, total cholesterol, triglyceride concentrations, and DBP were significantly higher in the 3GO group than in controls (Table 3). Participants with the haplotype’s minor allele had higher glucose, HbA1c, total cholesterol, and triglyceride concentrations in the blood than those with the major allele (Table 3). Interestingly, BMI was lower in the minor haplotype group than the major haplotype group, although BMI was higher in the 3GO group than in the control group. These results confirmed that the haplotype generated by the KCNQ1, ZPR1, APOA5, APOA1, and SIK3 genes significantly affected 3GO risk and that fasting serum glucose, blood pressure, and serum lipid profiles are significantly associated with 3GO risk.

Table 3. Adjusted means and standard deviations according to haplotype allele and control and 3GO groups.

| Haplotype   | Control (n = 28,440) | 3GO (n = 14,545) |
|-------------|---------------------|------------------|
|             | Major (n = 14,317)  | Minor (n = 1005) | Major (n = 613) | Minor (n = 74) |
| BMI (kg/m²) | 23.2 ± 2.71 b       | 23.1 ± 2.66 b    | 22.7 ± 2.58 b   | 25.9 ± 3.12 a  | 25.7 ± 3.04 a  | 25.7 ± 3.21 a+++ |
| Waist       | 78.4 ± 8.13 b       | 78.1 ± 8.13 b    | 76.8 ± 7.89 b   | 87.4 ± 8.41 a  | 87.4 ± 8.38 a  | 85.9 ± 7.77 a+++ |
| Hip         | 93.3 ± 5.53 b       | 93.2 ± 5.61 b    | 92.6 ± 5.31 b   | 96.4 ± 6.37 a  | 96.1 ± 6.52 a  | 95.9 ± 6.09 a+++ |
| Fasting     | 89.6 ± 9.29 c       | 89.8 ± 9.29 c    | 90.1 ± 9.23 c   | 132.6 ± 4.47 b | 131.5 ± 35.7 b | 138.9 ± 46.0 a+++ |
| HbA1c       | 5.49 ± 0.36 b       | 5.49 ± 0.35 b    | 5.49 ± 0.36 b   | 7.19 ± 1.38 a  | 7.21 ± 1.28 a  | 7.24 ± 1.53 a+++ |
| Total       | 200 ± 26.3 b        | 191 ± 26.1 b     | 191 ± 27.1 b    | 189 ± 44.3 b   | 186 ± 43.7 c   | 193 ± 43.8 a+++ |
| HDL (mg/dL) | 58.1 ± 11.9 a       | 56.9 ± 11.6 a    | 54.3 ± 10.8 b   | 46.6 ± 12.5 c  | 45.2 ± 11.5 c  | 44.3 ± 11.7 c+++ |
| TG (mg/dL)  | 88.5 ± 36.9 c       | 95.4 ± 38.4 c    | 104 ± 39.9 c    | 158 ± 75.8 c   | 181 ± 81.3 b   | 194 ± 91.8 a+++ |
| SBP (mmHg)  | 118 ± 12.5 b        | 118 ± 12.6 b     | 117 ± 12.7 b    | 132 ± 14.7 a   | 133 ± 15.4 a   | 134 ± 14.5 a+++ |
| DBP (mmHg)  | 73.1 ± 8.45 c       | 72.9 ± 8.47 c    | 72.6 ± 8.47 c   | 80.1 ± 9.69 b  | 80.4 ± 10.3 b  | 81.4 ± 9.68 a+++ |

1 BMI, body mass index; 2 HDL, high-density lipoprotein; 3 TG, triglyceride; 4 SBP, systolic blood pressure; 5 DBP, diastolic blood pressure. 

Haplotype was generated by KCNQ1_rs2237892, ZPR1_rs2075291, APOA5_rs662799, APOA1_rs5072, and SIK3_rs151139277 in 11q23. Major, heterozygote, and minor alleles of haplotype were divided into 3 categories (0–3; 4–6; and 7+ by tertiles as the major, heterozygote, and minor alleles, respectively. Adjusted means were calculated after adjusting for age, gender, residence area, BMI, energy, alcohol, and coffee intake, and physical activity. * Significantly different from major allele group at p < 0.05; ** p < 0.01; *** p < 0.001. + Significantly different by 3GO at p < 0.05; ++ p < 0.001. a,b,c Means without a common letter differ in the same row by Tukey’s test at p < 0.05.
3.4. 3GO-Related Parameters and Their Influences on 3GO Risk According to Haplotype

After adjustment for age, gender, residence area, BMI, physical activity, and energy, alcohol, and coffee intakes, considered as model 2, the minor alleles of haplotype containing KCNQ1, ZPR1, APOA5, APOA1, and SIK3 genetic variants were significantly associated with increased 3GO risk (OR = 3.230, 95% CI = 2.062–5.061, p < 0.001). We also analyzed the associations between the haplotype containing KCNQ1_rs2237892, ZPR1_rs2075291, APOA5_rs662799, APOA1_rs5072, and SIK3_rs151139277 and anthropometric and biochemical parameters. In model 2, the haplotype’s minor alleles were positively associated with SBP, HbA1c, serum glucose, total cholesterol HDL, and triglyceride concentration by 2.135-, 2.688-, 2.138-, 3.095-, 3.196-, and 3.568-fold respectively, as compared with the major alleles of haplotype (p < 0.001) (Table 4). However, waist circumferences, DBP, and SBP were not significantly associated with haplotype in models 1 or 2 (Table 4). Although obesity was a significant risk factor for MetS, and BMI was higher in the 3GO group than the control group, BMI was negatively associated with the minor alleles of haplotype by 0.757-fold compared to the haplotype’s major alleles (Table 4).

### Table 4. Adjusted odds ratios for the risk of 3GO and related parameters according to the allele of the haplotype of 11q23 loci after covariate adjustments.

|                  | Model 1 (n = 14,930) | Model 2 (n = 11,020) |
|------------------|----------------------|----------------------|
|                  | Major | Heterozygote | Minor | Heterozygote | Minor |
| 3GO              | 1     | 1.435 (1.274–1.616) *** | 2.938 (2.291–3.768) *** | 1.251 (1.009–1.548) * | 3.230 (2.062–5.061) *** |
| BMI              | 1     | 0.959 (0.907–1.014) ** | 0.762 (0.651–0.892) ** | 0.965 (0.910–1.024) * | 0.757 (0.541–0.893) *** |
| Waist circumference | 1     | 1.071 (0.966–1.191) | 0.791 (0.578–1.082) | 1.019 (0.849–1.223) | 0.709 (0.401–1.256) |
| SBP              | 1     | 1.134 (1.014–1.268) * | 1.689 (1.307–2.183) *** | 1.090 (0.877–1.354) | 2.135 (1.328–3.432) ** |
| DBP              | 1     | 1.171 (1.022–1.342) * | 1.435 (1.029–2.002) * | 1.188 (0.949–1.487) | 1.039 (0.548–1.971) |
| BP               | 1     | 1.171 (1.022–1.342) * | 1.435 (1.029–2.002) * | 1.121 (0.943–1.333) | 1.487 (0.966–2.289) |
| Serum glucose    | 1     | 1.123 (1.052–1.199) | 1.478 (1.255–1.740) *** | 1.141 (0.888–1.466) | 2.138 (1.222–3.742) ** |
| HbA1c            | 1     | 1.374 (1.214–1.556) * | 2.670 (2.056–3.467) *** | 1.365 (1.190–1.544) | 2.688 (2.048–3.529) *** |
| Serum total cholesterol | 1    | 1.115 (1.025–1.212) | 1.448 (1.183–1.771) ** | 0.940 (0.593–1.490) | 3.095 (1.374–6.972) ** |
| Serum HDL        | 1     | 1.320 (1.239–1.406) *** | 2.339 (2.020–2.708) *** | 1.318 (0.975–1.781) | 3.196 (1.761–5.801) *** |
| Serum TG         | 1     | 1.530 (1.421–1.648) | 2.744 (2.330–3.230) *** | 2.212 (1.535–3.187) | 3.658 (1.755–7.624) *** |

Values represent odds ratio and 95% confidence intervals after adjusting for covariates age, gender, residence area, and BMI (model 1) and covariates for model 1, plus intake of energy, alcohol, and coffee, physical activity (model 2). Haplotype generated with 5 single nucleotide polymorphisms (SNPs) was divided into 3 categories (0–3, 4–6, and 7–10) by tertiles as the major, heterozygote, and minor alleles, respectively. Haplotype’s major allele was the reference for both model 1 and model 2. * Significantly different from the major allele in logistic regression analysis at p < 0.05, ** p < 0.01, *** p < 0.001.
3.5. Haplotype–Environmental Interactions

Table 5 shows the impact of interactions between 11q23 loci and diet or lifestyle on the risk of 3GO. Interactions were observed between haplotype and nutrient intakes, including intakes of protein ($p = 0.033$), carbohydrates ($p = 0.012$), fat ($p = 0.008$), and undigested carbohydrates (dietary fiber; $p = 0.015$). As regards lifestyle factors, haplotype interacted with smoking status to influence 3GO risk ($p = 0.007$). However, alcohol intake, coffee intake, and physical activity did not interact with haplotype to modify the risk of 3GO.

After dichotomizing subjects into low- and high-intake groups, haplotype was found to interact with nutrient intake and 3GO risk. For those with the major haplotype allele, 3GO risk was increased by 3.3- and 3.2-fold in low-protein and low-fat intakes respectively (Table 5), and for low-protein and low-fat intake, the risk of 3GO was much higher for the minor alleles of haplotype than the major alleles (Figure 3A,B). Unlike that observed for protein or fat intake, the prevalence of 3GO had a higher association with the minor allele of haplotype in high-carbohydrate intake than for low-carbohydrate intake (Table 5), and 3GO frequencies were much higher for the minor allele of haplotype in a high-carbohydrate intake (Figure 3C). In contrast to carbohydrate intake, high dietary fiber (undigested carbohydrates) intake was highly associated with minor allele haplotype compared to low dietary fiber (Table 5). In low dietary fiber intake, 3GO frequencies were much higher in the minor allele than the major allele (Figure 3D). In the smokers and ex-smokers, 3GO risk was associated with the minor allele of haplotype more than in the non-smokers (Table 5), and smokers with the minor alleles had much higher 3GO frequencies (Figure 3E).

### Table 5. Adjusted 3GO for the risk of 3GO and related parameters according to the haplotype of KCNQ1_rs2237892, ZPR1_rs2075291, APOA5_rs662799, APOA1_rs5072, and SIK3_rs151139277, and interaction with lifestyles.

| Major Haplotype | Heterozygote Haplotype | Minor Haplotype | Haplotype–Nutrient Interaction |
|-----------------|------------------------|-----------------|-------------------------------|
| Low energy      | High energy            |                 |                               |
| 1 (n = 14,930)  | 1 (n = 13,862)          | 1 (n = 1102)    |                               |
| Low protein     | High protein           |                 |                               |
| 1.383 (1.219–1.569) *** | 1.926 (1.338–2.773) *** | 2.853 (2.198–3.701) *** | 0.533 |
| Low carbohydrate| High carbohydrate      |                 |                               |
| 1.622 (1.344–1.957) *** | 1.316 (1.128–1.533) *** | 2.640 (1.741–4.004) *** | 0.012 *|
| Low fat         | High fat               |                 |                               |
| 1.231 (1.039–1.459) ** | 1.648 (1.395–1.947) *** | 3.153 (2.234–4.450) *** | 0.008 *|
| Low diet fiber  | High diet fiber        |                 |                               |
| 1.462 (1.234–1.734) *** | 1.409 (1.193–1.664) *** | 3.673 (2.629–5.122) *** | 0.015 *|
| Low alcohol     | High alcohol           |                 |                               |
| 1.296 (1.106–1.520) ** | 1.628 (1.359–1.951) *** | 2.763 (2.001–3.817) *** | 0.786 |
| Low exercise    | High exercise          |                 |                               |
| 1.753 (1.391–2.211) *** | 1.354 (1.044–1.756) * | 2.413 (1.663–3.501) *** | 0.959 |
| Low coffee      | High coffee            |                 |                               |
| 1.479 (1.206–1.813) *** | 1.413 (1.235–1.658) *** | 2.751 (1.776–4.258) *** | 0.924 |
| Non-smoker      | Smoker + ex-smoker     |                 |                               |
| 1.119 (0.861–1.455) | 1.632 (0.887–3.002)   | 3.365 (2.012–5.630) *** | 0.007 **|

Values represent the odds ratio and 95% confidence intervals after adjusting for age, gender, residence area, BMI, intake of energy, alcohol, and coffee, and physical activity without the corresponding variables. Haplotype was generated with KCNQ1 (potassium voltage-gated channel subfamily Q member 1)_rs2237892, ZPR1 (ZPR1 zinc finger)_rs2075291, APOA5 (apolipoprotein A5)_rs662799, APOA1 (apolipoprotein A1)_rs5072, and SIK3 (SIK family kinase 3)_rs151139277. Haplotype was divided into 3 categories by tertiles as the major, heterozygote, and minor alleles. Reference was the major allele of the haplotype. Criteria of low and high definition of each parameter in interaction analysis: daily consumption less than estimated energy intake, less than 13% protein, 70% carbohydrate, and 15% fat of daily energy consumption, alcohol drinking > 20 g, coffee intake > 1 cup/day, and 90 min/day moderate physical activity. * Significantly different from major allele in logistic regression analysis at $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. 

Figure 3. Cont.
Figure 3. The proportion of participants with the major, heterozygous, and minor alleles of the haplotype in 11q23 according to high- and low-nutrient intake and smoking status. The proportions of 3GO were provided in a low and high intake of protein (A Cutoff: 13% energy), fat (B Cutoff: 15% energy), carbohydrate (C Cutoff: 70% energy), and dietary fiber (undigested carbohydrate; D Cutoff: 5 g/1000 kcal) intake and smoking status (E).

4. Discussion

Although BMI is low, Asians are more inclined to 3GO than whites [24,25]. This increment may be due to genetic differences and interaction with environmental factors. In the present study, we aimed to explore common genetic variants to influence 3GO risk and find the genetic variants–lifestyle interaction to influence 3GO risk in a city hospital-based cohort in Korean adults ≥ 40 years. To the best of our knowledge, this is the first study to explore the common genetic variants in 11q23 locus for 3GO risk and to show that complex genetic variants and environmental interactions, especially nutrient intakes, contribute to 3GO risk. Traditionally, the Asian diet is based on less refined rice, mostly with vegetables, but Asians consume refined rice with fewer vegetables in the last decades. These dietary pattern changes decrease undigestible carbohydrate (dietary fiber) intake and increase digestible carbohydrate intake. These changes may play a critical role in elevating 3GO risk through SNP–nutrient interactions [26].
Furthermore, Asians and Caucasians also consume different proportions of carbohydrates, fats, and proteins [27]. A very high carbohydrate intake with low dietary fiber and vitamin C is a culprit for metabolic syndrome in Asians [21,22]. The present study shows that 51.6% of 58,701 participants had either hypertension, hyperglycemia, or dyslipidemia in KoGES, and that 2.5% of them satisfied the criteria of 3GO. Participants with 3GO had lower energy intakes, higher proportions of carbohydrates, and lower proportions of fat, protein, and undigested carbohydrates in the diet than those without 3GO. These results indicated that adults need to consume higher proportions of protein, undigested carbohydrates, and adequate amounts of fat to reduce the incidence of 3GO.

*KCNQ1* is a voltage and lipid-gated potassium channel expressed in various tissues, including the myocardium, inner ear, kidney, lung, stomach, and intestines. *KCNQ1* affects insulin secretion, and its mutation is related to the prevalence of T2DM [28,29]. Its polymorphisms, located in intron 15, include rs2237892, rs2237895, and rs2237897, and are significantly related to impaired insulin secretion [30]. The rs2237892 SNP locus has also been related to T2DM susceptibility in East Asian and European populations [26,31]. The present study also showed that *KCNQ1* rs2237892 was one of the common genetic variants to influence 3GO risk. *ZPR1* is a cell proliferation and signal transduction regulator protein with various physiological functions [27], and rs964184 of *ZPR1* has been associated with T2DM hypertriglyceridemia in Asians [28]. The 11q23 locus haplotype, which includes *ZPR1* rs2075291, influences MetS risk with serum triglyceride and HDL levels [29], as shown in the present study. Thus, *ZPR1* rs2075291 is associated with hypo-LDL cholesterol, hypertriglyceridemia, and hyperglycemia.

The 11q23 locus also encodes *APOA5*, which has been implicated in regulating plasma triglyceride levels and the prevalence of MetS either independently or via complex gene–gene and/or gene–environment interactions. Consistent with the result of the present study, rs662799 of *APOA5* has been reported to increase the risk of MetS in Caucasians [32], Japanese [33], Koreans [34], and Chinese [35,36]. *APOAI* is a primary lipoprotein associated with serum HDL concentrations in T2DM [37], and rs5072 of *APOAI* is related to dyslipidemia in a gender-specific manner, as shown in the present study [38]. *SIK3* plays crucial mediating roles in the three essential cancer signalings: cell proliferation, inflammation, and metastasis [39], and has been related to anti-inflammatory activity [40] and chronic inflammation. Since chronic inflammation is a well-known precursor of MetS development and progression [41], *SIK3* can be associated with MetS risk. The present study shows that *SIK3* rs151139277 is related to 3GO, which suggests that inflammation may be associated with MetS. Summarizing these results, it appears that the 11q23 locus haplotype may be associated with hypertriglyceridemia, hypo-HDL-cholesterolemia, hyperglycemia, and inflammation, and contribute to blood flow disturbances, leading to hypertension.

In this present study, a high carbohydrate intake but low protein, fat, and undigested carbohydrate intakes were associated with significant risks of 3GO, especially in participants with the minor alleles of haplotype. Protein, carbohydrate, fat, and undigested carbohydrate intakes and smoking status interacted significantly with the 11q23 locus haplotype to modulate 3GO risk. Some Asians, including Koreans, consume a white rice-based diet high in carbohydrates but low in protein and fat, and previous studies have shown that Asian adults on a rice-based diet have a high incidence of MetS [22,42,43]. Due to the progression of the grain milling process, undigestible carbohydrate consumption has been reduced in Asians having rice as staple foods. Therefore, Asian adults, especially those with the minor allele of the 11q23 locus haplotype, should be recommended a high intake of dietary fiber, good-quality protein, and omega-3 fatty acid-rich foods, such as fruits, vegetables, and fish.

3GO risk is known to be reduced by an undigested carbohydrates-containing diet [44], as was observed in the present study. Dietary fiber can slow down digestion rates and promote cholesterol and glucose excretions into feces, thus reducing serum glucose and cholesterol levels. Undigested carbohydrate intake can also protect against the development of 3GO and regulate gut microbiota’s metabolic functions to prevent or treat metabolic.
In a meta-analysis, individuals that switched from a low-undigested carbohydrate diet (<15 g/day) to a high-undigested carbohydrate diet (25–29 g) were found to have a 1.3% lower mortality rate and a 0.6% lower incidence of heart disease, and to be at lower risk of developing T2DM, hypertension, dyslipidemia, and bowel cancer and of becoming obese [46,47]. Furthermore, undigested carbohydrate intake interacted with haplotype, and haplotype was more associated with 3GO risk in the low-undigested carbohydrate intake group than in the high-undigested carbohydrate intake group.

Tobacco seriously harms cardiovascular health, and thus, helping cardiovascular patients quit smoking and avoid secondhand smoke exposure can improve prognosis, and interestingly, the effect of smoking cessation can be equal or better than single drug treatments for metabolic diseases [48]. Furthermore, smoking elevates the risks of metabolic diseases [49]. We found that the haplotype in the 11q23 locus interacted with smoking to increase 3GO risk, and in smokers, the haplotype had a much stronger association with 3GO risk.

The present study was undertaken to explore common genetic variants associated with 3GO risk and the impacts of interactions between their haplotype at the 11q23 locus and intakes of carbohydrates, protein, fats, and undigested carbohydrate, and smoking status for the risk of 3GO and its components. This study shows that the increased prevalence of 3GO in Asian countries might be linked to genetic factors and their interactions with nutrient intake and smoking status. However, this study has several limitations. (1) The study was conducted using a case-control design, and thus, its results cannot establish causal relationships. (2) The study was conducted on an urban hospital-based cohort recruited from several cities without stratification, which means our results may not represent the Korean population, despite the large number of participants recruited ($n = 58,701$). (3) Nutrient intakes were calculated using self-estimates of food intakes determined by the SQFFQ, and thus, some daily nutrient intakes may have been inaccurate. However, the SQFFQ included 103 foods that Koreans consume frequently and demonstrated good validity and reproducibility compared with 12-day food records [50].

5. Conclusions

3GO was found to be associated with high BMIs, waist circumference, elevated fasting serum glucose, total cholesterol, triglyceride levels, systolic and diastolic pressures, and low serum HDL levels in our adult Asian cohort. We also found the haplotype generated from 5 SNPs ($\text{KCNQ1}_\text{rs2237892}$, $\text{ZPR1}_\text{rs2075291}$, $\text{APOA5}_\text{rs662799}$, $\text{APOA1}_\text{rs5072}$, and $\text{SIK3}_\text{rs151139277}$) in the 11q23 locus had a 3GO risk. Interactions of haplotype with carbohydrate, fat, protein, and undigested carbohydrate intakes and smoking status influenced 3GO risk. Low intakes of fat, protein, and undigested carbohydrate were positively associated with 3GO risk in individuals with the haplotype’s minor allele. Higher carbohydrate intake and smoking by individuals with the haplotype’s minor allele were also associated with an elevated risk of 3GO. We conclude that individuals having the minor allele of the 11q23 locus haplotype need to prohibit smoking and replace digestible carbohydrates intake into the consumption of undigested carbohydrates (mainly dietary fiber), high-quality protein, healthy fat, and calcium. The results of this study could be applied to prevent 3GO in those at genetically elevated 3GO risk by modifying lifestyles.

Author Contributions: S.P. designed this study, interpreted the data, and reviewed the manuscript. J.-Y.Z. formulated the research question, analyzed the data, and wrote the first draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the fund from the National Research Foundation of Korea (2019R1A2C1007203).

Institutional Review Board Statement: The study was conducted according to the Declaration of Helsinki’s guidelines and approved by the Institutional review board of the Korean National Institute of Health (KBP-2015-055). We additionally obtained approval from the Institutional Review Board of Hoseo University (1041231-150811-HR-034-01).
**Informed Consent Statement:** Informed consent was obtained from all participants involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Rochlani, Y.; Pothineni, N.V.; Kovelamudi, S.; Mehta, J.L. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds. *Ther. Adv. Cardiovasc. Dis.* 2017, 11, 215–225. [CrossRef]

2. Tadewos, A.; Egeno, T.; Amsalu, A. Risk factors of metabolic syndrome among hypertensive patients at Hawassa University Comprehensive Specialized Hospital, Southern Ethiopia. *BMC Cardiovasc. Disord.* 2017, 17, 218. [CrossRef]

3. Rakugi, H.; Ogihara, T. The metabolic syndrome in the Asian population. *Curr. Hypertens. Rep.* 2005, 7, 103–109. [CrossRef] [PubMed]

4. Grundy, S.M. Metabolic syndrome update. *Trends Cardiovasc. Med.* 2016, 26, 364–373. [CrossRef]

5. Hirano, T. Pathophysiology of Diabetic Dyslipidemia. *J. Atheroscler. Thromb.* 2018, 25, 771–782. [CrossRef]

6. Matsuzaka, T.; Shimano, H. New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease. *J. Diab. Investig.* 2020, 11, 532–534. [CrossRef]

7. Lu, S.; Bao, M.-Y.; Miao, S.-M.; Zhang, X.; Jia, Q.-Q.; Jing, S.-Q.; Shan, T.; Wu, X.-H.; Liu, Y. Prevalence of hypertension, diabetes, and dyslipidemia, and their additive effects on myocardial infarction and stroke: A cross-sectional study in Nanjing, China. *Ann. Transl. Med.* 2019, 7, 436. [CrossRef] [PubMed]

8. Park, S.; Kang, S. A minor allele of the haplotype located in the 19q13 loci is associated with a decreased risk of hyper-LDL-cholesterolemia, and a balanced diet and high protein intake can reduce the risk. *Lipids Health Dis.* 2020, 19, 178. [CrossRef]

9. Liu, M.; Jin, H.S.; Park, S. Protein and fat intake interacts with the haplotype of PTPN11_rs11066325, RPH3A_rs886477, and OAS3_rs2072134 to modulate serum HDL concentrations in middle-aged people. *Clin. Nutr.* 2020, 39, 942–949. [CrossRef] [PubMed]

10. Katakami, N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. *J. Atheroscler. Thromb.* 2018, 25, 27–39. [CrossRef] [PubMed]

11. Zhang, J.; Yang, J. Clinical Study of Intervention Sport Therapy on Blood Pressure, Blood Lipid and Blood Glucose of the Elderly Patients with “Three Highs”. *Western J. Trad. Chin. Med.* 2016, 29, 1004–6852.

12. Wen, P.E.; Li, Q.Y. Effect of individualized lifestyle habits on the diagnosis and treatment of patients with “Three High Diseases”. *Hainan Med.* 2019, 30, 1003–6350.

13. Elman, B.A. *Rethinking East Asian Languages, Vernaculars, and Literacies, 1000–1919*; Brill: Leiden, The Netherlands, 2014.

14. Kim, Y.; Han, B.G.; KoGES Group. Cohort Profile: The Korean Genome and Epidemiology Study (KoGES) Consortium. *Int. J. Epidemiol.* 2017, 46, e20. [CrossRef]

15. Cho, N.H.; Kim, K.M.; Choi, S.H.; Park, K.S.; Jang, H.C.; Kim, S.S.; Sattar, N.; Lim, S. High Blood pressure and its association with incident diabetes over 10 years in the Korean Genome and Epidemiology Study (KoGES). *Diabetes Care* 2015, 38, 1333–1338. [CrossRef]

16. Unger, T.; Borghi, C.; Charchar, F.; Khan, N.A.; Poulter, N.R.; Prabhakaran, D.; Ramirez, A.; Schlaich, M.; Stergiou, G.S.; Tomaszewski, M.; et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension* 2020, 75, 1334–1357. [CrossRef]

17. Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: Principles of pathogenesis and therapy. *Lancet* 2005, 365, 1333–1346. [CrossRef]

18. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020. *Diabetes*. 2020, 43, S14–S31.

19. Sukhorukov, V.N.; Karagodin, V.P.; Orekhov, A.N. Modern methods of diagnosis dyslipidemia. *Patol. Fiziol. Eksp. Ter.* 2016, 60, 65–72. [PubMed]

20. Park, S.; Daily, J.W.; Zhang, X.; Jin, H.S.; Lee, H.J.; Lee, Y.H. Interactions with the MC4R rs17782313 variant, mental stress and energy intake and the risk of obesity in Genome Epidemiology Study. *Nutr. Metab.* 2016, 13, 38. [CrossRef] [PubMed]

21. Park, S.; Ham, J.O.; Lee, B.K. Effects of total vitamin A, vitamin C, and fruit intake on risk for metabolic syndrome in Korean women and men. *Nutrition* 2015, 31, 111–118. [CrossRef] [PubMed]

22. Park, S.; Ahn, J.; Lee, B.K. Very-low-fat diets may be associated with increased risk of metabolic syndrome in the adult population. *Clin. Nutr.* 2016, 35, 1159–1167. [CrossRef]

23. Hong, K.W.; Kim, S.H.; Zhang, X.; Park, S. Interactions among the variants of insulin-related genes and nutrients increase the risk of type 2 diabetes. *Nutr. Res.* 2018, 51, 82–92. [CrossRef]

24. Li, J.; Dong, Y.; Wu, T.; Tong, N. Differences between Western and Asian type 2 diabetes patients in the incidence of vascular complications and mortality: A systematic review of randomized controlled trials on lowering blood glucose. *J. Diabetes* 2016, 8, 824–833. [CrossRef] [PubMed]
25. Gadgil, M.D.; Anderson, C.A.; Kandula, N.R.; Kanaya, A.M. Dietary patterns are associated with metabolic risk factors in South Asians living in the United States. J. Nutr. 2015, 145, 1211–1217. [CrossRef] [PubMed]
26. Tsai, F.J.; Yang, C.F.; Chen, C.C.; Chuang, L.M.; Lu, C.H.; Chang, C.T.; Wang, T.Y.; Chen, R.H.; Shiu, C.F.; Liu, Y.M.; et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet. 2010, 6, e1000847. [CrossRef]
27. Galcheva-Gargova, Z.; Gangwani, L.; Konstantinov, K.N.; Mikrut, M.; Theroux, S.J.; Enoch, T.; Davis, R.J. The cytoplasmic zinc finger protein ZPR1 accumulates in the nucleus of proliferating cells. Mol. Biol. Cell. 1998, 9, 2963–2971. [CrossRef] [PubMed]
28. Tokoro, F.; Matsuoka, R.; Abe, S.; Arai, M.; Noda, T.; Watanabe, S.; Horibe, H.; Fujimaki, T.; Oguri, M.; Kato, K.; et al. Association of a genetic variant of the ZPR1 zinc finger gene with type 2 diabetes mellitus. Biomed. Rep. 2015, 3, 88–92. [CrossRef]
29. Fallah, M.S.; Sedaghatkhahayat, B.; Guity, K.; Akbarnia, B.; Azizi, F.; Daneshpour, M.S. The Relation between Metabolic Syndrome Risk Factors and Genetic Variations of Apolipoprotein V in Relation with Serum Triglyceride and HDL-C Level. Arch. Iran. Med. 2016, 19, 46–50.
30. Qi, Q.; Li, H.; Loos, R.J.F.; Liu, C.; Wu, Y.; Hu, F.B.; Wu, H.; Lu, L.; Yu, Z.; Lin, X. Common variants in KCNQ1 are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Human Mol. Genet. 2009, 18, 3508–3515. [CrossRef]
31. Yasuda, K.; Miyake, K.; Horikawa, Y.; Hara, K.; Osawa, H.; Furuta, H.; Hirota, Y.; Mori, H.; Jonsson, A.; Sato, Y.; et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat. Genet. 2008, 40, 1092–1097. [CrossRef]
32. Maças, A.; Kissali, P.; Horvatoth, K.; Mohâs, M.; Markô, L.; Csöngész, V.; Faragó, B.; Järomi, L.; Magyari, L.; Sáfrány, E.; et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol. Oncol. Res. 2007, 13, 243–247. [CrossRef] [PubMed]
33. Yamada, Y.; Kato, K.; Hibino, T.; Yokoi, K.; Matsuo, H.; Segawa, T.; Ichihara, S.; Yoshida, H.; Satoh, K.; et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 2007, 191, 298–304. [CrossRef]
34. Kim, Y.R.; Hong, S.H. Association of Apolipoprotein A5 Gene Polymorphisms with Metabolic Syndrome in the Korean Population. Genet. Test. Mol. Biomark. 2016, 20, 130–136. [CrossRef]
35. Hsu, L.A.; Ko, Y.L.; Chang, C.J.; Teng, M.S.; Wu, S.; Hu, C.F. Apolipoprotein A5 gene -1131T/C polymorphism is associated with metabolic disorders: A Cohort Study from a Chinese population. Sci. Rep. 2016, 6, 385. [CrossRef] [PubMed]
36. Xu, C.; Bai, R.; Zhang, D.; Li, Z.; Zhu, H.; Lai, M.; Zhi, Y. Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: Evidence from a case-control study in China and a meta-analysis. PLoS ONE 2013, 8, e56216. [CrossRef]
37. Reynoso-Villalpando, G.L.; Sevillano-Collantes, C.; Valle, Y.; Moreno-Ruiz, I.; Padilla-Gutiérrez, J.R.; Del Cañiz-Gómez, F.J. ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. Endocrinol. Diabetes Nutr. 2019, 66, 502–511. [CrossRef] [PubMed]
38. Bai, W.; Kou, C.; Zhang, L.; You, Y.; Yu, W.; Hua, W.; Li, Y.; Yu, Y.; Zhao, T.; Wu, Y. Functional polymorphisms of the APOA1/C3/A4/A5-ZPR1-BUD13 gene cluster are associated with dyslipidemia in a sex-specific pattern. PeerJ 2019, 6, e6175. [CrossRef]
39. Amara, S.; Majors, C.; Roy, B.; Hill, S.; Rose, K.L.; Myles, E.L.; Tiriveedi, V. Critical role of SIK3 in mediating high salt and IL-17 synergy leading to breast cancer cell proliferation. PLoS ONE 2017, 12, e0180097. [CrossRef]
40. Darling, N.J.; Toth, R.; Arthur, J.S.C.; Clark, K. Inhibition of SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages. Biochem. J. 2017, 474, 521–537. [CrossRef] [PubMed]
41. Sun, Z.; Jiang, Q.; Li, J.; Guo, J. The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Signal. Transduct. Target. Ther. 2020, 5, 150. [CrossRef]
42. Feng, R.; Du, S.; Chen, Y.; Zheng, S.; Zhang, W.; Na, G.; Li, Y.; Sun, C. High carbohydrate intake from starchy foods is positively associated with metabolic disorders: A Cohort Study from a Chinese population. Sci. Rep. 2015, 5, 16919. [CrossRef] [PubMed]
43. Song, S.; Young Paik, H.; Song, W.O.; Song, Y. Metabolic syndrome risk factors are associated with white rice intake in Korean adolescent girls and boys. Br. J. Nutr. 2015, 113, 479–487. [CrossRef]
44. Ramdath, D.D.; Padhi, E.M.; Sarfaraz, S.; Renwick, S.; Duncan, A.M. Beyond the Cholesterol-Lowering Effect of Soy Protein: A Review of the Effects of Dietary Soy and Its Constituents on Risk Factors for Cardiovascular Disease. Nutrients 2017, 9, 324. [CrossRef] [PubMed]
45. Holst, H.D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 2017, 8, 172–184. [CrossRef]
46. Soliman, G.A. Dietary Fiber, Atherosclerosis, and Cardiovascular Disease. Nutrients 2019, 11, 1155. [CrossRef] [PubMed]
47. Reynolds, A.; Mann, J.; Cummings, J.; Winter, N.; Mete, E.; Te Morenga, L. Carbohydrate quality and human health: A series of systematic reviews and meta-analyses. Lancet 2019, 393, 434–445. [CrossRef]
48. Bilano, V.; Gilmour, S.; Moffett, T.; d’Espaignet, E.T.; Stevens, G.A.; Commar, A.; Tuyl, E.; Hudson, I.; Shibuya, K. Global trends and projections for tobacco use, 1990–2025: An analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet 2015, 385, 966–976. [CrossRef]
49. Kumar, G.; Mohan, S.; Yadav, L.; Arora, M. Global Tobacco Surveys: Information for Action by Cardiologists. Glob. Heart 2012, 7, 99–105. [CrossRef] [PubMed]
50. Ahn, Y.; Kwon, E.; Shim, J.E.; Park, M.K.; Joo, Y.; Kimm, K.; Park, C.; Kim, D.H. Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. Eur. J. Clin. Nutr. 2007, 61, 1435–1441. [CrossRef]